HPV Vaccine
17
3
5
5
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
0.0%
0 terminated out of 17 trials
100.0%
+13.5% vs benchmark
24%
4 trials in Phase 3/4
40%
2 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (17)
Immunogenicity of Fractional Dose of the HPV Vaccines
Intradermal, Fractional Dose of HPV Vaccines:
A Randomized Trial of Digital Interventions to Increase HPV Vaccination Intentions Among Nigerian Caregivers
Strengthening HPV Immunization Through EPI Leveraged Delivery
Evaluation of a Vaccine Chatbot on HPV Vaccine Confidence and Hesitancy
Persistence of Immune Response Six Years After One Dose of 9vHPV Vaccine Among Male and Female Students
HPV Vaccination in HIV Infected and HIV Uninfected Adolescents in Eswatini
HPV Ends Here: Increasing Uptake of the HPV Vaccine
Effectiveness of Vaccine Chatbot on HPV Vaccine Awareness and Vaccination in China
Adaptation Of An HPV Education Resource To Promote HPV Vaccination
Impact of a Mock-up Fact-checking Extension on HPV Vaccine Misinformation: A Survey Experiment
Two Domestic HPV Vaccines and Imported HPV Vaccines in Women Aged 13-14 Years Study on Immunogenicity
Prevalence of ENT Diseseas
Mobile Coaching to Improve HPV Vaccine Delivery
Antibody Response to Prophylactic QHPV Vaccine at 48 Months Among HIV-infected Girls and Boys
State Immunization Information Systems to Improve HPV Vaccination Rates
Retrospective Cohort Study of the Effectiveness of the Prophylactic Vaccine Against the Human Papilloma Virus in the Prevention of Recurrence in Women Who Have Received an Excisional Therapy by HSIL / CIN.